cellulitis; sicker; heat; nose bleed with clots after that; Green drainage; sinus infection; allergic reaction at the inject sight; fatigued; chills; bright red; swollen; I thought my left arm was going to fall off; This spontaneous case was reported by a nurse and describes the occurrence of CELLULITIS (cellulitis) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 007J212A and 069H21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Skin cancer (Stage 1 squamous cell), Seizures (due to a car accident), Accident automobile (Car accident), Transient ischemic attack (4 TIAs), Clinical trial participant (2003 was out for 3 weeks with MERS (said they tested positive)) in 1997, Skin cancer excision in September 2021 and Squamous cell carcinoma excision in July 2021. Concurrent medical conditions included Asthma, Cardiac arrhythmia and Allergy (with a prescribed epi pen). Concomitant products included LEVETIRACETAM (KEPRA), FLECAINIDE, MONTELUKAST SODIUM (SINGULAIR), PANTOPRAZOLE SODIUM SESQUIHYDRATE (PANTOPRAZOLE 40), FEXOFENADINE HYDROCHLORIDE (ALLEGRA 24 HOUR), SALBUTAMOL (ALBUTEROL HFA), HCTZ, MUPIROCIN and TETANUS VACCINE for an unknown indication.   On 23-Dec-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Jan-2022, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced CELLULITIS (cellulitis) (seriousness criterion medically significant), ILLNESS (sicker), FEELING HOT (heat), EPISTAXIS (nose bleed with clots after that), DISCHARGE (Green drainage), SINUSITIS (sinus infection), VACCINATION SITE REACTION (allergic reaction at the inject sight), FATIGUE (fatigued), CHILLS (chills), VACCINATION SITE ERYTHEMA (bright red), VACCINATION SITE SWELLING (swollen) and VACCINATION SITE PAIN (I thought my left arm was going to fall off). The patient was treated with CEFALEXIN MONOHYDRATE (KEFLEX [CEFALEXIN MONOHYDRATE]) at a dose of 500 milligram and AMOXICILLIN, CLAVULANIC ACID (AUGMENT [AMOXICILLIN;CLAVULANIC ACID]) at a dose of 875 mg (after sinus infection). At the time of the report, CELLULITIS (cellulitis), ILLNESS (sicker), FEELING HOT (heat), EPISTAXIS (nose bleed with clots after that), DISCHARGE (Green drainage), VACCINATION SITE REACTION (allergic reaction at the inject sight), VACCINATION SITE ERYTHEMA (bright red), VACCINATION SITE SWELLING (swollen) and VACCINATION SITE PAIN (I thought my left arm was going to fall off) outcome was unknown and SINUSITIS (sinus infection), FATIGUE (fatigued) and CHILLS (chills) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication included Elipta 200 m.  It was stated that they could not get into her primary care doctor, so she went to the urgent care. Stated they saw their primary doctor on the 9th of February and they provided further instructions. Caller states their podiatrist. She was forced to take the shot by the company she worked for after telling them that she had problem (with previous vaccines). She do not had history of COVID diagnosis.  Company comment: This Spontaneous case concerns an elderly female patient with medical history of Automobile accident, seizures, cardiac arrhythmia and TIAs, experienced the unexpected serious event Cellulitis, on an unknown date after second dose of mRNA-1273. At the time of reporting, the event had not resolved. The benefit-risk relationship of mRNA-1273 is not affected by this report.   This case was linked to MOD-2022-491980 (Patient Link).; Sender's Comments: This Spontaneous case concerns an elderly female patient with medical history of Automobile accident, seizures, cardiac arrhythmia and TIAs, experienced the unexpected serious event Cellulitis, on an unknown date after second dose of mRNA-1273. At the time of reporting, the event had not resolved. The benefit-risk relationship of mRNA-1273 is not affected by this report.